Valeant Pharmaceuticals (VRX) PT, Estimates Cut at Jefferies after Dropping Philidor
Tweet Send to a Friend
Jefferies analyst David Steinberg lowered estimates and his price target on Valeant Pharmaceuticals (NYSE: VRX) to $172.00 (from $224.00) after ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
